NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTHI NeOnc Technologies Holdings

盘后交易 10-23 19:32:37 EDT

3.27

+0.32

+10.85%

盘后3.28

+0.01+0.31%

19:30 EDT

最高3.55	最低2.90	成交量38.09万
今开2.95	昨收2.95	日振幅22.03%
总市值9,419万	流通市值4,812万	总股本2,881万
成交额126.05万	换手率2.59%	流通股本1,472万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":3.27,"timestamp":1792785600000,"preClose":2.95,"halted":0,"volume":380852,"hourTrading":{"tag":"盘后","latestPrice":3.28,"preClose":3.27,"latestTime":"19:30 EDT","volume":864,"amount":2831.0579136,"timestamp":1792798204034,"change":0.01,"changeRate":0.003058,"amplitude":0.030581},"delay":0,"changeRate":0.10847457627118638,"floatShares":14715982,"shares":28805400,"eps":-2.136127,"marketStatus":"盘后交易","change":0.32,"latestTime":"10-23 19:32:37 EDT","open":2.95,"high":3.55,"low":2.9001,"amount":1260513.671866,"amplitude":0.220305,"askPrice":3.58,"askSize":200,"bidPrice":2.75,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-2.136127,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792800000000},"marketStatusCode":4,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":2.95,"postHourTrading":{"tag":"盘后","latestPrice":3.28,"preClose":3.27,"latestTime":"19:30 EDT","volume":864,"amount":2831.0579136,"timestamp":1792798204034,"change":0.01,"changeRate":0.003058,"amplitude":0.030581},"volumeRatio":3.836125},"requestUrl":"/m/hq/s/NTHI","defaultTab":"news","newsList":[{"id":"1175120042","title":"Neonc Technologies控股赎回6,000股A系列优先股，耗资600万美元现金，未发行普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175120042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175120042?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:55","pubTimestamp":1789649728,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings公司近日宣布，已动用600万美元现金完成对6,000股A系列优先股的赎回操作，整个过程中未涉及任何普通股的发行。此次赎回行动，展现了公司在资本结构调整上的审慎策略，同时也凸显了其现金流的充沛与灵活性。值得留意的是，这一举措并不涉及股本稀释，对现有股东的权益未造成任何影响。市场观察人士指出，此类赎回行为通常被视为公司优化资本结构的积极信号，可能预示着管理层对公司未来前景的信心。目前，Neonc Technologies Holdings的股价表现如何，尚需进一步观察市场对这一消息的反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159616138","title":"NeOnc Technologies Holdings宣布完成1500万美元注册直接发行定价，纳斯达克规则下按市价面向新旧机构投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=1159616138","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159616138?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:01","pubTimestamp":1788955294,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings, Inc.今日正式对外宣布，其总额达1500万美元的注册直接发行已完成定价。此次发行严格遵守纳斯达克相关规则，按照市场价格进行，认购方涵盖多位新晋及现有机构投资者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168273292","title":"NeOnc Technologies Holdings 公布鼻内给药 Neo100 针对复发性 IDH1 突变型高级别胶质瘤的积极 2a 期顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168273292","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168273292?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:01","pubTimestamp":1786536077,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings 宣布，其针对复发性 IDH1 突变型高级别胶质瘤患者开发的鼻内给药产品 Neo100，在 2a 期临床试验中取得了积极的顶线数据。这一结果无疑为攻克这一难治性脑瘤带来了新的希望，并进一步验证了该公司在肿瘤精准治疗领域的创新实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120133280","title":"Neonc科技公布2026年第二季度财报，并确认将于8月12日发布Neo100二期a阶段关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120133280","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120133280?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:02","pubTimestamp":1786366978,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings（NTHI）今日正式披露了其2026年第二季度的财务表现。与此同时，该公司还郑重确认，其备受瞩目的Neo100二期a阶段临床试验的顶线数据，定于8月12日揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177518473","title":"Neonc Technologies：FDA认定其CMC开发方案合理，但附加生产变更条件","url":"https://stock-news.laohu8.com/highlight/detail?id=1177518473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177518473?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:17","pubTimestamp":1784121457,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局在审阅Neonc Technologies Holdings的CMC开发方案后，认为其整体思路合理。然而，监管机构针对生产过程中的变更提出了附加条件，要求公司在实施相关调整时必须满足特定要求。CMC开发是药物获批上市的关键环节，涉及药品的生产工艺、质量控制和稳定性等核心方面。FDA的认可意味着公司在该领域的技术路径基本获得肯定，而附加条件则明确了后续优化生产中需遵循的监管框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122121747","title":"Neonc Technologies获阿联酋IND批准推进Neo100，全球开发版图扩张，静待二期数据里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1122121747","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122121747?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:05","pubTimestamp":1782219921,"startTime":"0","endTime":"0","summary":"Neonc Technologies公司宣布，其候选药物Neo100已获得阿联酋（UAE）的新药临床试验（IND）批准。这一进展标志着该公司全球开发战略的进一步拓展，为即将到来的二期临床试验数据里程碑铺平了道路。随着监管绿灯的亮起，Neo100在中东地区的临床开发路径得以开启，有望加速其作为潜在疗法的全球评估进程。公司正积极筹备后续的临床工作，市场也正密切关注其后续关键数据的发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172142321","title":"Neonc Technologies拟通过私募发行最多500万美元A系列可转换优先股 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1172142321","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172142321?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:05","pubTimestamp":1781258739,"startTime":"0","endTime":"0","summary":"根据提交至美国证券交易委员会（SEC）的文件，Neonc Technologies Holdings计划以私募方式发行最多价值500万美元的A系列可转换优先股。\n此次融资活动旨在为公司注入新的资本，以支持其业务发展计划。可转换优先股通常为投资者提供固定股息，并赋予其在特定条件下将股份转换为普通股的权利。\n该交易的具体条款，包括转换价格、股息率及最终发行规模，将在后续的正式协议中最终确定。公司通过此类非公开融资，可更为灵活地获取发展所需资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neonc.com","stockEarnings":[{"period":"1week","weight":0.0727},{"period":"1month","weight":-0.1449},{"period":"3month","weight":-0.1399},{"period":"6month","weight":-0.3828},{"period":"1year","weight":-0.6722},{"period":"ytd","weight":-0.6433}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neonc Technologies Holdings, Inc.于2023年1月5日注册成立，为特拉华州公司。作为一家临床阶段的生物制药公司，该公司一直专注于建立颅内恶性肿瘤的治疗方法，即位于大脑的侵袭性癌症。这些癌症类型包括原发性脑癌，如胶质母细胞瘤，和继发性脑癌，它们是通过全身其他癌症的转移扩散而来的，如黑色素瘤或乳腺癌和肺癌。大脑局限性恶性肿瘤特别难以治疗，因为血脑屏障阻止了大多数药物治疗剂有效进入大脑。因此，这些患者面临着预后不良和平均预期寿命缩短的问题。NeOnc正在开发新的药物递送方法，用于与新的候选药物联合使用。","exchange":"NASDAQ","name":"NeOnc Technologies Holdings","nameEN":"NeOnc Technologies Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NeOnc Technologies Holdings,NTHI,NeOnc Technologies Holdings股票,NeOnc Technologies Holdings股票老虎,NeOnc Technologies Holdings股票老虎国际,NeOnc Technologies Holdings行情,NeOnc Technologies Holdings股票行情,NeOnc Technologies Holdings股价,NeOnc Technologies Holdings股市,NeOnc Technologies Holdings股票价格,NeOnc Technologies Holdings股票交易,NeOnc Technologies Holdings股票购买,NeOnc Technologies Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}